Literature DB >> 22296740

Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death.

Jeffrey J Swigris1, Amy L Olson, Tristan J Huie, Evans R Fernandez-Perez, Joshua Solomon, David Sprunger, Kevin K Brown.   

Abstract

BACKGROUND: In studies of idiopathic pulmonary fibrosis (IPF), whites makeup the vast majority of subjects. Whether ethnic/racial differences in idiopathic pulmonary fibrosis occur in the general population is unknown.
METHODS: To compare the presence of IPF between ethnic/racial groups of U.S. decedents from 1989 to 2007 by using the National Center for Health Statistics database.
RESULTS: There were 251,058 U.S. decedents with IPF; 87.2% were non-Hispanic whites (White), 5.1% were non-Hispanic African American (black), 5.4% were Hispanic, and 2.2% were from other ethnic/racial groups (other). Whites coded with IPF died older than those in the other groups (77.9 years vs. 72.1 years for blacks, 75.3 years for Hispanics, and 75.6 years for others; p < 0.0001 for all pairwise comparisons). When controlling for age and for sex, compared with whites, both Hispanics and Others were more likely to be coded with IPF (OR = 1.47, 95% CI 1.44-1.49, p < 0.0001 and OR = 1.29, 95% CI 1.26-1.36, p < 0.0001 respectively), while blacks were significantly less likely to be coded with IPF (OR = 0.48, 95% CI 0.47-0.49, p < 0.0001). Among decedents with IPF, Hispanics were more likely, and blacks were less likely, than whites to die from IPF (OR = 1.24, 95% CI 1.20-1.29, p < 0.0001 and OR = 0.91, 95% CI 0.87-0.94, p < 0.0001).
CONCLUSION: From 1989 to 2007, black decedents were less-and Hispanics were more-likely than whites to die of/with IPF. Research is needed to determine if genetic differences between ethnic/racial groups explain these findings. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22296740      PMCID: PMC3294009          DOI: 10.1016/j.rmed.2012.01.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Racial disparities in clinical trials.

Authors:  Talmadge E King
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

3.  Familial pulmonary fibrosis in the United States.

Authors:  Momen M Wahidi; Marcy C Speer; Mark P Steele; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  Chest       Date:  2002-03       Impact factor: 9.410

4.  Validity of demographic characteristics on the death certificate.

Authors:  P D Sorlie; E Rogot; N J Johnson
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

5.  Comparability of marital status, race, nativity, and country of origin on the death certificate and matching census record.

Authors:  T Z Hambright
Journal:  Vital Health Stat 2       Date:  1969-05

6.  Comparability of the death certificate and the 1986 National Mortality Followback Survey.

Authors:  G S Poe; E Powell-Griner; J K McLaughlin; P J Placek; G B Thompson; K Robinson
Journal:  Vital Health Stat 2       Date:  1993-11

7.  Familial interstitial pulmonary fibrosis: a large family with atypical clinical features.

Authors:  Ranji Chibbar; John A Gjevre; Francis Shih; Heather Neufeld; Edmond G Lemire; Derek A Fladeland; Donald W Cockcroft
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

8.  Factors that influence African-Americans' willingness to participate in medical research studies.

Authors:  V L Shavers; C F Lynch; L F Burmeister
Journal:  Cancer       Date:  2001-01-01       Impact factor: 6.860

9.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

10.  Familial idiopathic pulmonary fibrosis: clinical features and outcome.

Authors:  Hong-Lyeol Lee; Jay H Ryu; Michael H Wittmer; Thomas E Hartman; James F Lymp; Henry D Tazelaar; Andrew H Limper
Journal:  Chest       Date:  2005-06       Impact factor: 9.410

View more
  21 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Impaired Lung Function, Lung Disease, and Risk of Incident Dementia.

Authors:  Pamela L Lutsey; Nemin Chen; Maria C Mirabelli; Kamakshi Lakshminarayan; David S Knopman; Keith A Vossel; Rebecca F Gottesman; Thomas H Mosley; Alvaro Alonso
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

3.  Access to Lung Transplantation in the United States: The Potential Impact of Access to a High-volume Center.

Authors:  Ernest G Chan; J W Awori Hayanga; Marie Tuft; Matthew R Morrell; Pablo G Sanchez
Journal:  Transplantation       Date:  2020-07       Impact factor: 4.939

4.  The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries.

Authors:  Anna L Peljto; Moises Selman; Dong Soon Kim; Elissa Murphy; Laura Tucker; Annie Pardo; Jung Su Lee; Wonjun Ji; Marvin I Schwarz; Ivana V Yang; David A Schwartz; Tasha E Fingerlin
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

5.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

Review 6.  Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs.

Authors:  Coline H M van Moorsel; Thijs W Hoffman; Aernoud A van Batenburg; Dymph Klay; Joanne J van der Vis; Jan C Grutters
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

Review 7.  Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

Authors:  Jaana Kaunisto; Eija-Riitta Salomaa; Ulla Hodgson; Riitta Kaarteenaho; Marjukka Myllärniemi
Journal:  BMC Pulm Med       Date:  2013-08-20       Impact factor: 3.317

Review 8.  Epidemiology of idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard
Journal:  Clin Epidemiol       Date:  2013-11-25       Impact factor: 4.790

Review 9.  The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population.

Authors:  Raphael Borie; Bruno Crestani; Philippe Dieude; Hilario Nunes; Yannick Allanore; Caroline Kannengiesser; Paolo Airo; Marco Matucci-Cerinic; Benoit Wallaert; Dominique Israel-Biet; Jacques Cadranel; Vincent Cottin; Steven Gazal; Anna L Peljto; John Varga; David A Schwartz; Dominique Valeyre; Bernard Grandchamp
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.

Authors:  Taroh Satoh; Akihiko Gemma; Shoji Kudoh; Fumikazu Sakai; Kensei Yamaguchi; Toshiaki Watanabe; Megumi Ishiguro; Shogo Inoshiri; Makiko Izawa; Kenichi Sugihara; Yuh Sakata
Journal:  Jpn J Clin Oncol       Date:  2014-09-10       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.